hemispherx-news - 500 Beiträge pro Seite
eröffnet am 17.02.00 23:09:45 von
neuester Beitrag 09.03.00 01:53:36 von
neuester Beitrag 09.03.00 01:53:36 von
Beiträge: 7
ID: 65.622
ID: 65.622
Aufrufe heute: 0
Gesamt: 754
Gesamt: 754
Aktive User: 0
ISIN: US00901B1052 · WKN: A2PREX · Symbol: AIM
0,4613
USD
-3,03 %
-0,0144 USD
Letzter Kurs 17:28:36 NYSE Arca
Neuigkeiten
14:45 Uhr · globenewswire  |
15.04.24 · globenewswire |
11.04.24 · globenewswire |
10.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 5,8600 | +81,42 | |
| 0,5499 | +66,85 | |
| 0,9300 | +54,46 | |
| 6,5500 | +54,12 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,4900 | -14,38 | |
| 209,70 | -15,55 | |
| 6,4550 | -17,77 | |
| 2,3000 | -19,01 | |
| 2,0900 | -40,52 |
Feedback
hallo
manche von euch können sich vielleicht noch dran erinnern, wie hemispherx (heb) von assensio ( amerik. shortseller) runtergeprügelt wurde. wie die heutigen news zeigen, ev. zu unrecht. es ist wohl klar, was da für ein potential in ampligen (dem produkt von heb) drinsteckt. aber vorsicht. seit der assenso-geschichte ist der ruf von hemispherx mehr als angekratzt. die guten news häufen sich allerdings in letzter zeit. investment ist aber immernoch sehr spekulativ.
hier die news
hemisrherx-news
Hemispherx Files for HIV Emergency Treatment IND and Phase II/III
Trials
PHILADELPHIA, Feb. 17 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today announced that it has filed for HIV Emergency Treatment
IND and Phase II and Phase III trials with the Food and Drug Administration.
The Company`s new HIV Emergency Treatment IND application is intended to be used to study the effects of Ampligen on the growing number of people with
AIDS (PWA`s) who are developing resistance to their currently approved regimens, some of whom have been left with no other clinical options. Hemispherx`s Phase
II and Phase III trials are intended to study the effects of Ampligen in combination with several Highly Active Antiretroviral Therapy (HAART) regimens, which have
been structured by Anderson Clinical Research.
``This is a very exciting development at a critical time in the epidemic when the promise of Highly Active Antiretroviral Therapy has begun to fade,`` said Dr. William
A. Carter, Chairman and Chief Executive Officer of Hemispherx. ``Clinical trials and Emergency Treatment Protocols need to begin now to target the growing
number of patients who are quickly exhausting their therapeutic options.``
These new filings follow the lead of other studies, which were presented at the IBT Conference in Boston last December, that showed Ampligen is highly synergistic
with 12 of the 14 approved HIV medications. To date, Ampligen has been studied in 126 patients and has been consistently well tolerated in its trials. The new
studies will evaluate not only the previous surrogate markers, such as the improvements in Cell Mediated Immunity, but how Ampligen, in Immune Base Therapy,
may further reduce viral load in people with AIDS.
HEB`s Web Site: http://www.hemispherx.com
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations
affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission.
Accordingly, actual results may differ materially from those in any forward-looking statements.
SOURCE: Hemispherx Biopharma, Inc.
More Quotes and News:
Hemispherx Biopharma, Inc (AMEX:HEB - news)
Related News Categories: biotech, medical/pharmaceutical
und hier noch eine etwas ältere news, die ein bißchen besser zeigt, um was es geht. (aufgrund dieser news habe ich mir damals heb ins depot gelegt, aber nur mit kohle, die ich locker abschreiben könnte)
Hemispherx Announces New Approach to HIV-Inhibition; Test Results
Show Potential Advantages of Ampligen(R) as Anti-HIV Agent
PHILADELPHIA, Dec. 15 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today announced that recent independent laboratory test results
show potential advantages of its product Ampligen® as an anti-HIV agent.
According to findings presented today at the Immune-Based Therapy-2 (IBT-2) conference in Boston, 12 out of 14 drugs approved by the Food and Drug
Administration (FDA) as anti-HIV agents demonstrated pronounced antiviral effectiveness with Ampligen®, with no examples of inhibiting the effectiveness of other
drugs. Also, all members of the newest class of powerful HIV inhibitors, termed protease inhibitors, were enhanced by Ampligen. In fact, enhancement magnitudes
varied from several hundred percent enhancement to more than 800% enhancement.
The new results, developed by independent researchers at the University of California at Irvine, examined all 14 FDA-approved anti-HIV agents. IBT-2 is a
clinical/research workshop sponsored by a group of nine AIDS service-and-research entities in the Boston area.
The new test-tube studies examined various concentrations of the different drugs under conditions designed to simulate the clinical situation in patients. Using a
pharmacological approach termed ``Mixed Drug Effect Analyses,`` researchers determined whether a new drug addition dramatically increased antiviral effectiveness
(known as drug synergy), had no effect whatsoever (known as neutral compound) or inhibited the effectiveness of the other drugs (known as drug antagonism).
``Pronounced antiviral synergy represents a potentially new therapeutic approach to long-term suppression of HIV,`` said William A. Carter, Chairman and Chief
Executive Officer of Hemispherx. ``In recent years, powerful drug cocktails have subdued the virus to undetectable levels in many patients. But various studies have
recently found that the virus comes roaring back in the majority of patients because the virus survived therapy by hiding in certain cells and tissues. Further
intensification of antiretroviral treatment by therapies that are less toxic and complex are a promising avenue of investigation. Double-stranded RNA technology,
which includes Ampligen®, represents a mechanism of action distinctly different from that of the available 14 FDA-approved drugs.``
Hemispherx Biopharma, Inc. is a biopharmaceutical company specializing in new therapeutic approaches to HIV/AIDS, Chronic Fatigue Syndrome (CFS) and
hepatitis B/C utilizing the immune system. It has offices in Philadelphia, Belgium and France and new drug development facilities in the Washington, D.C., area.
Hemispherx was recently listed on the ``Russell 2000`` Index of small capitalization stocks.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations
affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission.
Accordingly, actual results may differ materially from those in any forward-looking statements.
SOURCE: Hemispherx Biopharma, Inc.
viele grüße-no risk no fun tgfn
manche von euch können sich vielleicht noch dran erinnern, wie hemispherx (heb) von assensio ( amerik. shortseller) runtergeprügelt wurde. wie die heutigen news zeigen, ev. zu unrecht. es ist wohl klar, was da für ein potential in ampligen (dem produkt von heb) drinsteckt. aber vorsicht. seit der assenso-geschichte ist der ruf von hemispherx mehr als angekratzt. die guten news häufen sich allerdings in letzter zeit. investment ist aber immernoch sehr spekulativ.
hier die news
hemisrherx-news
Hemispherx Files for HIV Emergency Treatment IND and Phase II/III
Trials
PHILADELPHIA, Feb. 17 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today announced that it has filed for HIV Emergency Treatment
IND and Phase II and Phase III trials with the Food and Drug Administration.
The Company`s new HIV Emergency Treatment IND application is intended to be used to study the effects of Ampligen on the growing number of people with
AIDS (PWA`s) who are developing resistance to their currently approved regimens, some of whom have been left with no other clinical options. Hemispherx`s Phase
II and Phase III trials are intended to study the effects of Ampligen in combination with several Highly Active Antiretroviral Therapy (HAART) regimens, which have
been structured by Anderson Clinical Research.
``This is a very exciting development at a critical time in the epidemic when the promise of Highly Active Antiretroviral Therapy has begun to fade,`` said Dr. William
A. Carter, Chairman and Chief Executive Officer of Hemispherx. ``Clinical trials and Emergency Treatment Protocols need to begin now to target the growing
number of patients who are quickly exhausting their therapeutic options.``
These new filings follow the lead of other studies, which were presented at the IBT Conference in Boston last December, that showed Ampligen is highly synergistic
with 12 of the 14 approved HIV medications. To date, Ampligen has been studied in 126 patients and has been consistently well tolerated in its trials. The new
studies will evaluate not only the previous surrogate markers, such as the improvements in Cell Mediated Immunity, but how Ampligen, in Immune Base Therapy,
may further reduce viral load in people with AIDS.
HEB`s Web Site: http://www.hemispherx.com
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations
affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission.
Accordingly, actual results may differ materially from those in any forward-looking statements.
SOURCE: Hemispherx Biopharma, Inc.
More Quotes and News:
Hemispherx Biopharma, Inc (AMEX:HEB - news)
Related News Categories: biotech, medical/pharmaceutical
und hier noch eine etwas ältere news, die ein bißchen besser zeigt, um was es geht. (aufgrund dieser news habe ich mir damals heb ins depot gelegt, aber nur mit kohle, die ich locker abschreiben könnte)
Hemispherx Announces New Approach to HIV-Inhibition; Test Results
Show Potential Advantages of Ampligen(R) as Anti-HIV Agent
PHILADELPHIA, Dec. 15 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today announced that recent independent laboratory test results
show potential advantages of its product Ampligen® as an anti-HIV agent.
According to findings presented today at the Immune-Based Therapy-2 (IBT-2) conference in Boston, 12 out of 14 drugs approved by the Food and Drug
Administration (FDA) as anti-HIV agents demonstrated pronounced antiviral effectiveness with Ampligen®, with no examples of inhibiting the effectiveness of other
drugs. Also, all members of the newest class of powerful HIV inhibitors, termed protease inhibitors, were enhanced by Ampligen. In fact, enhancement magnitudes
varied from several hundred percent enhancement to more than 800% enhancement.
The new results, developed by independent researchers at the University of California at Irvine, examined all 14 FDA-approved anti-HIV agents. IBT-2 is a
clinical/research workshop sponsored by a group of nine AIDS service-and-research entities in the Boston area.
The new test-tube studies examined various concentrations of the different drugs under conditions designed to simulate the clinical situation in patients. Using a
pharmacological approach termed ``Mixed Drug Effect Analyses,`` researchers determined whether a new drug addition dramatically increased antiviral effectiveness
(known as drug synergy), had no effect whatsoever (known as neutral compound) or inhibited the effectiveness of the other drugs (known as drug antagonism).
``Pronounced antiviral synergy represents a potentially new therapeutic approach to long-term suppression of HIV,`` said William A. Carter, Chairman and Chief
Executive Officer of Hemispherx. ``In recent years, powerful drug cocktails have subdued the virus to undetectable levels in many patients. But various studies have
recently found that the virus comes roaring back in the majority of patients because the virus survived therapy by hiding in certain cells and tissues. Further
intensification of antiretroviral treatment by therapies that are less toxic and complex are a promising avenue of investigation. Double-stranded RNA technology,
which includes Ampligen®, represents a mechanism of action distinctly different from that of the available 14 FDA-approved drugs.``
Hemispherx Biopharma, Inc. is a biopharmaceutical company specializing in new therapeutic approaches to HIV/AIDS, Chronic Fatigue Syndrome (CFS) and
hepatitis B/C utilizing the immune system. It has offices in Philadelphia, Belgium and France and new drug development facilities in the Washington, D.C., area.
Hemispherx was recently listed on the ``Russell 2000`` Index of small capitalization stocks.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations
affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission.
Accordingly, actual results may differ materially from those in any forward-looking statements.
SOURCE: Hemispherx Biopharma, Inc.
viele grüße-no risk no fun tgfn
hi,
achtet doch mal darauf, wie sich die eigentümerstruktur bei h. in den letzten 12 monaten verändert hat. es steigen immer mehr seriöse fonds in den wert ein!
warum wohl?
gruss
peterli
achtet doch mal darauf, wie sich die eigentümerstruktur bei h. in den letzten 12 monaten verändert hat. es steigen immer mehr seriöse fonds in den wert ein!
warum wohl?
gruss
peterli
Hemispherx wird seinen Weg machen, da bin ich überzeugt. Hatte mit ein Freund im November 98 empfohlen. Bin immer noch drin und will so schnell auch nicht wieder raus. Charttechnisch absolut kaufenswert. Auch bei den derzeitigen Kursen. Stay long
Riecht nach Konsolidierung! Von 12 auf 20 in 1 Woche ist doch etwas
heftig, odrrr? (Habs netterweise ab 14 mitmachen dürfen...)
Götz
heftig, odrrr? (Habs netterweise ab 14 mitmachen dürfen...)
Götz
hallo götz
heftig schon, ist aber für die biotechs eher normal zur zeit.
gruß tgfn
heftig schon, ist aber für die biotechs eher normal zur zeit.
gruß tgfn
Trading Spotlight
Nach der Konsolidierung bis 15 E besteht jetzt wieder Kaufgelegenheit!
Götz
Götz
Bin auch drin seit 16 Euro.
Ging ja gestern gut ab an der AMEX...+18%
Werden auch ganz ordentlich in Frankfurt gehandelt.
Ging ja gestern gut ab an der AMEX...+18%
Werden auch ganz ordentlich in Frankfurt gehandelt.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,31 | |
| +0,68 | |
| -1,34 | |
| +3,40 | |
| -1,56 | |
| +0,15 | |
| -0,50 | |
| -0,92 | |
| 0,00 | |
| +1,41 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 155 | ||
| 142 | ||
| 61 | ||
| 58 | ||
| 54 | ||
| 40 | ||
| 38 | ||
| 33 | ||
| 31 | ||
| 30 |
hemispherx-news
